Ernexa Therapeutics (ERNAW) Cash from Restructuring (2021)
Ernexa Therapeutics (ERNAW) reported Cash from Restructuring of $5.8 million for Q1 2021.
Ernexa Therapeutics (ERNAW) Cash from Restructuring (2021) Analysis & Trends
Ernexa Therapeutics has reported Cash from Restructuring for 1 years, with the latest figure at $5.8 million in Q1 2021.
- For the quarter ending Q1 2021, Cash from Restructuring changed N/A year-over-year to $5.8 million; the trailing twelve-month figure through Dec 2021 stood at $5.8 million (changed N/A YoY), and the FY2021 full-year result was $5.8 million, changed N/A from the prior year.
- Cash from Restructuring for Q1 2021 stood at $5.8 million.
- The five-year high for Cash from Restructuring was $5.8 million in Q1 2021, with the low at $5.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 5.77 Mn |